Eighty-eight previously autografted (78 transplanted twice and 10 once) myeloma patients who had no cryopreserved stem cells available for possible future use received G-CSF for mobilization of stem cells. Onefourth of the patients had progressive disease at the time of apheresis. All patients had received 200 mg/m 2 melphalan for the first transplant. The interval between the preceding transplant and the harvest was 5-68 months (median 29). A total of 0.46-9.16 (median 3.03) ؋10
In patients with malignant diseases relapsing after highdose therapy and autotransplantation, further treatment, depending upon the patient's clinical condition and the nature of the disease, may comprise conventional chemo- therapy, additional high-dose therapy-transplant procedures, or symptomatic treatment. 1, 2 Patients relapsing after an autograft often have no previously harvested cells available, and further high-dose therapy can only be performed using cells harvested in a subsequent remission. 2 In addition to permitting further high-dose chemotherapy, the availability of additional autologous cells can open up avenues to novel salvage immunotherapy based upon dendritic cells and cytotoxic T lymphocytes.
The standard therapy of multiple myeloma at the University of Arkansas for Medical Sciences comprises tandem autotransplantation, 3, 4 and enough cells for two autografts are harvested after initial cytoreduction prior to the first transplant. 5 A number of autografted myeloma patients experience disease progression eventually, and some may benefit from third autograft procedures. 6 Occasionally, adequate cells for multiple transplant procedures are harvested at the outset, and repeat high-dose therapy can be delivered using these cells as the source of hematopoietic support. 1 However, previously cryopreserved progenitor cells are not routinely available for such patients. We have systematically collected and cryopreserved peripheral blood stem cells from myeloma patients after one or two preceding autografts if no cryopreserved progenitor cells were available.
This report summarizes our experience with stem cell mobilization in previously autografted myeloma patients. The findings have practical implications for all patients who have been autografted for malignant diseases and for patients receiving interferon-␣ for any disease, especially chronic myeloid leukemia (CML).
Patients and methods
Between 1994 and 1997, 88 patients with multiple myeloma who had undergone one (n = 10) or two (n = 78) autografts at the University of Arkansas for Medical Sciences received granulocyte colony-stimulating factor (G-CSF) for collection of peripheral blood stem cells for possible future use. None had cryopreserved cells available because all previously harvested cells (usually collected after a combination of high-dose cyclophosphamide with granulocytemacrophage colony-stimulating factor or G-CSF) had been used up for prior autotransplantation. Patient characteristics are shown in Table 1 . 
Prior autograft
All patients had received 200 mg/m 2 melphalan for the first autograft, whereas the conditioning regimen for the second transplant was variable, and comprised melphalan alone (n = 59) or in combination with other agents (usually totalbody irradiation or cyclophosphamide; n = 19). The 78 patients autografted twice prior to apheresis had been transplanted with cells collected prior to the first transplant.
Post-transplant maintenance therapy
Patients on post-transplant maintenance therapy with interferon-␣ (n = 71) discontinued the drug for 2-3 months prior to the collection. Patients not receiving interferon-␣ post transplant usually received dexamethasone as maintenance therapy (20-40 mg daily for 4 days every 3-4 weeks) which was stopped only at the time of apheresis.
Disease status at the time of collection
Disease progression after the preceding transplant but before the post-transplant stem cell collection was seen in 22 (25%) patients. Twenty-one of these 22 patients received myelosuppressive chemotherapy (19 cyclophosphamidedexamethasone-etoposide-cisplatin and two cyclophosphamide-vincristine-doxorubicin-dexamethasone) before the harvest. The remaining 75% had stable disease after transplantation (complete or partial remission, or no response following transplant). At the time of apheresis, 63 patients were in remission (28 PR and 35 CR; Ͻ5% plasma cells in the marrow) and 25 patients had active disease. Criteria for remission have been published elsewhere.
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Mobilization
All patients received G-CSF as a single agent for mobilization. The drug was administered as a single daily subcutaneous injection starting on day 1. Since the study was not prospective, the G-CSF dose used for mobilization was variable, and was chosen for an individual patient by the physician seeing the patient prior to mobilization, and was rounded off to the nearest vial size (300 or 480 g). Over 75% of the patients received at least 780 g G-CSF daily. The actual dose administered on a per kg basis was variable ( Table 1) ; 75% of the patients received у10 g/kg.
Apheresis
Leukapheresis began on day 4 on Cobe Spectra (Lakewood, CO, USA) or Fenwal CS-3000 cell separators (Deerfield, IL, USA), and was usually continued until at least 2 ϫ 10 6
CD34
ϩ cells/kg were collected. However, the duration of apheresis was variable depending upon patient and physician preference. The technique for the enumeration of CD34 ϩ cells has been described earlier.
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Statistical analysis
Continuous variables were compared using the KruskallWallis test and categoric variables with the 2 or Fisher's exact test.
The following factors were analyzed for their effect on the post-transplant CD34 ϩ cell yields: months of therapy prior to the original stem cell collection, number of CD34 ϩ cells harvested originally, number of preceding autografts, conditioning regimen for the second autograft, duration of maintenance interferon-␣ therapy after autograft, interval between the preceding autograft and the harvest, disease status at the time of the harvest, disease progression prior to harvest, myelosuppressive chemotherapy between transplant and harvest, the leukocyte and platelet counts at the time of starting G-CSF prior to the harvest, and the G-CSF dose.
For the 12 patients autografted using these cells, posttransplant hematologic recovery was studied in relation to the CD34 ϩ cell dose infused. Table 1 shows the G-CSF dose administered, the number of aphereses, and the mononuclear and CD34 ϩ cell yields. The minimum target number of CD34 ϩ cells (2 ϫ 10 6 /kg) was reached in 67 (76%) patients ( Table 2 ). The number of aphereses varied widely. /kg) required fewer aphereses to complete the collection, presumably because of good mobilization and therefore good collection with each single apheresis.
Results
Factors affecting CD34
ϩ cell yields Table 3 shows that patients who had received no interferon-␣ after transplantation (n = 17) or less than 6 months of interferon-␣ (n = 15) (1-6 months, median 3) had better collections than those who had received more than 6 months of interferon-␣ (n = 56; 7-61 months, median 21). Among the 71 patients receiving interferon-␣, there was no significant correlation between the duration of interferon therapy and CD34 ϩ cell yields (␥ = Ϫ0.03). Patients with good blood counts prior to starting G-CSF for post-transplant mobilization (platelets у200 ϫ 10 9 /l and leukocytes у5 ϫ 10 9 /l), and good CD34 ϩ cell yields before the original autograft (у5 ϫ 10 6 /kg) also had higher cell yields. There was a non-significant trend for higher CD34 ϩ cell yields with increasing transplant-harvest durations and higher G-CSF doses. None of the other factors, Table 3 Factors affecting CD34 ϩ cell yields including the extent of marrow plasmacytosis amongst the 25 patients with active disease, affected CD34 ϩ cell yields. Table 4 shows the factors affecting CD34 ϩ cell yields significantly in multivariate analysis. When pre-transplant variables were included in the analysis, a higher pre-transplant CD34 ϩ cell yield was the most powerful predictor of good post-transplant collections. A platelet count of у200 ϫ 10 9 /l before starting mobilization, duration of interferon-␣ therapy р6 months, and a leukocyte count of у5 ϫ 10 9 /l before starting mobilization also affected CD34 ϩ cell yields favorably. When pre-transplant variables were excluded from the analysis, a platelet count of у200 ϫ 10 9 /l before starting mobilization was the most powerful predictor of good posttransplant collections. Absence of myelosuppressive chemotherapy after transplantation and duration of interferon-␣ therapy р6 months also affected CD34 ϩ cell yields favorably. There was a trend for patients with leukocyte counts of у5 ϫ 10 9 /l before starting mobilization (P = 0.07) and those harvested more than 3 years after the preceding transplant (P = 0.08) to have better collections.
Factors affecting cell collections for patients autografted twice before collection (n = 78) were essentially similar (data not shown).
Characteristics of patients yielding у5 ϫ 10
6 CD34 ϩ cells
The 12 patients in whom у5 ϫ 10 6 CD34 ϩ cells/kg were collected had received a significantly higher G-CSF dose (median 1200 g/day) compared with the 76 in whom the cell yields were lower (median 960 g/day, P = 0.003).
Eight of these 12 had received р6 months of interferon-␣ compared with 24 of 76 among the remainder (P = 0.03).
These patients also had higher CD34 ϩ cell yields originally prior to the first transplant (median 27.94 vs 11.41 ϫ 10 6 /kg, P = 0.093), although the proportion of patients with original yields Ͻ5.0 ϫ 10 6 CD34 ϩ /kg was comparable (1 of 12 vs 17 of 76; P = 0.4).
There were no other differences between the two groups including myelosuppressive chemotherapy after transplantation (1 of 12 vs 20 of 76; P = 0.3).
Table 4
Factors affecting CD34 ϩ cell yields favorably in multivariate analysis of the whole group of patients No interferon therapy is counted as duration of therapy р6 months.
Autotransplantation using these cells
As of December 1997, 12 patients have been autografted using these cells (1.03-6.02 ϫ 10 6 CD34 ϩ cells/kg, median 2.76). This was the third autotransplant for all the patients. The number of CD34 ϩ cells infused and hematologic recovery parameters are shown in Table 5 . While neutrophil recovery to 0.5 ϫ 10 9 /l was prompt in the 11 evaluable patients (8-13 days, median 10), platelet recovery to 50 ϫ 10 9 /l was delayed or incomplete in six. With this small a number of patients, no obvious relationship could be detected between hematologic recovery and the number of CD34 ϩ cells infused, or other factors such as the original CD34 ϩ collection, the platelet count at the time of the post-transplant harvest, and prolonged interferon-␣ therapy prior to the harvest (Table 5 ).
Discussion
Our data show that it is possible to collect peripheral blood stem cells with G-CSF stimulation in patients autografted previously. While it is known that increasing extent of preceding therapy, especially with chemotherapy agents known to be toxic to stem cells, compromises the eventual collection of stem cells, 5 the feasibility of collecting stem cells after a preceding transplant has never been systematically studied.
It was our practice initially to utilize all available cells This patient received an infusion of a small quantity of allogeneic cells the day after the autograft to induce 'hit-and-run' graft-versus-myeloma. No recovery until the last available blood count (time shown). Next available count 6 months later shows Ͼ200 ϫ 10 9 /l platelets.
for tandem autotransplantation. However, with increasing disease-free survival of these patients and the availability of effective salvage therapy for relapse, 1, 6 it was decided to ensure that additional cells were in store for all patients. We have used third autotransplants successfully to salvage a number of myeloma patients relapsing after two preceding autotransplants, 6, 7 and on rare occasions have performed fourth high-dose therapy procedures (unpublished data).
The aim of the study was not to study hematologic recovery when these cells are used for transplantation or the feasibility/utility of third transplants in myeloma. The limited data we have suggest that these cells can be used successfully for transplantation although platelet recovery may be slow and incomplete. The apparent lack of correlation between the tempo of hematologic recovery and the CD34 ϩ cell dose, which is contrary to observations for usual autograft procedures using cells collected prior to transplantation, 5 may simply be due to small patient numbers and should be interpreted with caution. Alternatively, stromal cell damage or some alteration in the nature of the stem cells due to replicative stress may also make a contribution. 8 It is not inconceivable that repeat high-dose therapy may be a useful salvage procedure for patients with other malignant diseases relapsing after a previous autograft. Our observation therefore has practical significance for patients with malignant diseases who are in remission after autotransplantation if they have no more stem cells in store and there is a possibility of disease recurrence.
The observation of a strong correlation between the CD34 ϩ cell yields before and after autotransplantation, while interesting, is not practically relevant for two reasons: firstly, it is not a variable which can be manipulated in a patient in whom a post-autograft apheresis is being contemplated, and secondly, in patients with large CD34 ϩ cell yields, it is now routine at our center to only infuse the number of cells required for prompt engraftment (2 ϫ 10 6
CD34
ϩ cells/kg if prior therapy duration is Ͻ12 months, and 5 ϫ 10 6 CD34 ϩ cells/kg if prior therapy duration is over 12 months) 5 and keep the remaining cells in storage for possible future use.
The correlation between good blood counts before commencing G-CSF for mobilization and good CD34 ϩ cell yields is not surprising because platelet and leukocyte counts are excellent indicators of marrow function and reserve.
In practical terms, the observation of the adverse effect of prolonged interferon therapy on cell yields is the most interesting and relevant one. Interferon-␣ was discontinued approximately 2-3 months before the harvest; whether this period was adequate to reverse all its myelosuppressive action in terms of compromising stem cell yields is unknown and needs to be studied further. This is analogous to the prolonged suppression of myeloid progenitor cells seen in interferon-treated patients with CML in whom autologous cells are to be harvested. 9 The data on collection of peripheral blood stem cells in CML patients who have achieved Philadelphia chromosome negativity after interferon-␣ therapy are very limited. 9 It is possible that collection of adequate quantities of stem cells may become difficult in these patients on account of interferon-␣. Therefore, extrapolating these observations, it may be worthwhile collecting normal progenitors in CML patients (who are not candidates for allogeneic transplantation) at the time of diagnosis after myelosuppressive chemotherapy 10, 11 before commencing long-term interferon therapy.
Periodic intensive consolidation chemotherapy posttransplant is being utilized to prolong remissions in myeloma 12, 13 and breast cancer. 14 Our data suggest that collection of additional stem cells in these patients may become difficult.
It is not surprising to see that the factors affecting the collection are similar among patients autografted once or twice before collection because all the patients autografted twice received cells collected prior to the first transplant for both transplants. However, the number of patients autografted once is small (n = 10), and if there is additional stromal cell damage with two transplants which may affect apheresis yields or subsequent engraftment, this study does not have the power to detect it.
We conclude that it is possible to harvest blood stem cells in patients who have been autografted previously after mobilization with G-CSF. Patients with normal leukocyte and platelet counts at the time of starting G-CSF are more likely to yield good quantities of cells. In patients who are to receive interferon-␣ maintenance therapy, the cells are best collected when the duration of interferon-␣ therapy is less than 6 months. This observation has practical implications for patients autografted for other diseases who have no stored stem cells, those being considered for post-transplant consolidation chemotherapy, and patients with CML who are receiving interferon-␣.
